BioSpace News Archive

Bio-Rad Laboratories, Inc. will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market.

Keystone Bio announced today their participation as a keynote speaker at the Sachs 6th Annual Neuroscience Innovation Forum in San Francisco, CA.

Longeveron Inc. today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023.

Legacy Healthcare, a clinical-stage biopharmaceutical company today announced positive results from the RAAINBOW phase 2/3 randomized placebo-controlled trial evaluating Coacillium 22.25% cutaneous solution in children and adolescents with moderate and severe alopecia areata, a debilitating autoimmune condition causing disfiguring scalp hair loss.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced the closing of a €130 million Series C equity financing.

While much of the mystery surrounding sepsis remains, Feinstein Institutes for Medical Research scientists published in Cellular & Molecular Immunology the discovery of a protein that inhibits the body’s ability to clear bacteria, opening new avenues of therapeutic research.

Mission Bio announced a new publication in Nature from researchers at the Ragon Institute of MGH, MIT, and Harvard and Brigham and Women’s Hospital using Mission Bio’s Tapestri® Platform to identify phenotypic signatures of hidden human immunodeficiency virus 1 -infected immune cells that allow the virus to evade immune response.

Zensights LLC has named Barry Brandstetter to its advisory board, effective January 2, 2023.

HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603.

RemSleep Holdings Inc., a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, provides a corporate update and letter to shareholders from CEO Tom Wood.